Monoclonal antibodies (MAb) solutions are a major class of biopharmaceuticals with various applications. However, challenges such as a high viscosity at the required MAb concentrations need to be addressed at an early development stage.
Monoclonal antibodies are important biopharmaceuticals for treating diseases such as cancer, inflammation, allergies, infectious diseases and cardiovascular diseases. The challenge is, however, the low potency of MAb and the high viscosity of concentrated MAb solutions. Injection volumes bigger than 1.5 mL are not suitable for subcutaneous administration.
Due to the low potency, MAb solutions often need to be concentrated in order to cover the required dosage at a reasonable volume. But as a consequence viscosity is a technical issue for the stability and manufacturability of MAb solutions and negatively affects the usability for subcutaneous injection.
Download the Application Note to find out more.
UK productivity hindered by digital skills deficit – report
This is a bit of a nebulous subject. There are several sub-disciplines of 'digital skills' which all need different approaches. ...